Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive RNA-seq analysis in the prostate of benign prostatic hyperplasia (BPH) rats exposed to testosterone and Estradiol

ABSTRACT: Comprehensive RNA-seq analysis in the prostate of benign prostatic hyperplasia (BPH) rats exposed to testosterone and Estradiol

PROVIDER: PRJNA900575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Copy number analysis of BPH (Benign Prostatic Hyperplasia)

Project description:Copy number analysis of BPH (Benign Prostatic Hyperplasia)

| PRJNA510968 | ENA

Genome-wide analysis of prostatic tissue gene expression from patients with benign prostatic hyperplasia

Project description:Analysis of gene expression in prostatic tissue from BPH patients with and without SRD5A2 gene methylation. The hypothesis is that BPH patients with DNA methylation of the SRD5A2 gene promoter have impaired conversion of testosterone to dihydrotestosterone, and therefore may use an alternative signaling pathway for prostatic tissue growth. Here, we compare gene expression profiles of SRD5A2-methylated vs. unmethylated prostatic tissue to nominate alternative biological pathways relevant in each molecular subtype of BPH.

2017-10-01 | GSE101486 | GEO

Expression data from benign prostatic hyperplasia samples and normal controls

Project description:To further development of our gene expression signature for benign prostatic hyperplasia, we conducted expression profiles of BPH and normal samples.

2020-05-28 | GSE119195 | GEO

Different expressed genes in epithelium and stromal of Benign Prostatic Hyperplasia

2011-08-10 | GSE31323 | GEO

Therapeutic potential of pomegranate juice-derived nanovesicles in nude mouse benign prostatic hyperplasia (BPH) xenograft model

Project description:Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms affect a large percentage of the male population and places a substantial burden on the world health system. Current therapies include 5-alpha reductase inhibitors and alpha-blockers that are only partially effective and pose a huge economic burden, emphasizing the urgent need for effective, economical therapies. We isolated nanovesicles from pomegranate juice (Punica Granatum) (referred to as ‘POM-NVs’) and report to our knowledge for the first time, that these vesicles possess therapeutic potential against BPH. Following extensive characterization of POM-NVs, we tested their therapeutic potential in vitro using BPH1 cell line and identified a potential anti-proliferative and pro-apoptotic effect. We further tested these vesicles using a clinically relevant xenograft mouse BPH model derived from human BPH tissues. Remarkably, POM-NVs could reverse the BPH phenotype conferred by TGF-β mediated signaling and induced epithelial-to-mesenchymal (EMT) reversal, leading to the restoration of prostate epithelial states in vivo and in vitro. Furthermore, these vesicles attenuated bone morphogenic protein 5 (BMP5) signaling, a cardinal alteration that is instrumental in driving BPH. Considering the large incidences of BPH and its associated economic burdens, our study has important implications and can potentially improve the clinical management of BPH.

2023-07-18 | PXD043608 | Pride

Different expressed genes in epithelium and stromal of Benign Prostatic Hyperplasia

Project description:To identify the genes differently expressed in the epithelium and the stromal of Benign Prostatic Hyperplasia (BPH), we collect the epithelium and the stromal from the patients with benign prostatic hyperplasia by laser micro-dissection. And then, Affymetrix HG-U133_Plus_2 gene-chip was used to detect and compare the expression level of genes. To find which genes are most abundantly expressed in epithelium and stromal and what is the role of these genes in the pathogenesis of BPH. 8 prostate tissues were collected from patients undergone transurethral resection of the prostate (TURP) with informed consent. Each tissue was embedded in O.C.T and subsequently used for laser micro-dissection. The total RNA was isolated from each sample and equally mixed for gene-chip assay.

2011-08-09 | E-GEOD-31323 | biostudies-arrayexpress

Transcription profiling of doxazosin response, an alpha(1)-adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH)

Project description:BACKGROUND: We used cDNA microarray analysis to obtain insights into the mechanisms of action of doxazosin, an alpha(1)-adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH). METHODS: Hierarchical clustering analysis and significance analysis of microarray (SAM) were performed to identify genes differentially expressed between untreated stromal cells cultured from normal tissue and BPH, and changes in gene expression induced by doxazosin. Transcript levels of selected genes were validated by real-time reverse-transcription polymerase chain reaction (RT-PCR). RESULTS: Hierarchical clustering analyses separated untreated normal and BPH cells. Sixty-seven genes whose expression varied at least twofold after doxazosin treatment in both normal and BPH cells were identified, as were 93 genes differentially regulated in normal versus BPH cells. Molecular targets consistent with tumor necrosis factor (TNF)-alpha-related activity were identified. CONCLUSIONS: Normal versus BPH stromal cells differ in global gene transcription. Doxazosin induced gene expression changes relevant to proliferation/apoptosis, immune defense, cell-cell signaling/signal transduction, and transcriptional regulation.

2005-11-07 | E-SMDB-2934 | biostudies-arrayexpress

Comprehensive RNA-seq analysis in the prostate of benign prostatic hyperplasia (BPH) rats exposed to testosterone and Estradiol

Project description:Effects of excessive testosterone and estradiol on gene expression of rat prostate

2025-01-29 | GSE217800 | GEO

High Throughput Sequencing of a Mouse Model for Benign Prostatic Hyperplasia (BPH)

Project description:High Throughput Sequencing of a Mouse Model for Benign Prostatic Hyperplasia (BPH)

| PRJNA703842 | ENA

Comparative serum proteome profiling of canine benign prostatic hyperplasia before and after castration

Project description:Benign prostatic hyperplasia (BPH) is the most prevalent prostatic condition in older intact dogs; nonetheless, clinical diagnosis and management remain inconsistent. This study employed in-solution digestion coupled with nano-liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS) to assess serum proteome profiling of dogs with BPH and those dogs after castration.

2024-10-11 | PXD046059 | JPOST Repository

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data